Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals Inc (APLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Apellis to Present Data on APL-2 in Complement 3 Glomerulopathy at ASN Kidney Week 2019

Company also provides an update on plans in nephrology

APLS : 27.83 (+0.07%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals Inc., (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 27.83 (+0.07%)
Apellis Pharmaceuticals (APLS) Catches Eye: Stock Jumps 5.2%

Apellis Pharmaceuticals (APLS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

ANIK : 57.87 (-0.70%)
APLS : 27.83 (+0.07%)
Solidia Technologies Names Doug Robinson CFO and Paul Majsztrik Director of Applied Research

Solidia Technologies(R) announces the appointments of Doug Robinson as chief financial officer and Paul Majsztrik as director of Applied Research. Coupled with recent additions to its Board of Directors,...

APLS : 27.83 (+0.07%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 27.83 (+0.07%)
Apellis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 27.83 (+0.07%)
Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration

Apellis Pharmaceuticals Inc., (NASDAQ:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 27.83 (+0.07%)
Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes

Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 27.83 (+0.07%)
Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes

Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 27.83 (+0.07%)
Apellis Pharmaceuticals Announces Proposed Private Offering of $200 Million of Convertible Senior Notes

Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 27.83 (+0.07%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 27.83 (+0.07%)
Xceedance and Oasis LMF Announce On-Demand Catastrophe Modelling Services

Xceedance, a global provider of insurance consulting, managed services, technology, data sciences, and blockchain solutions, announces the availability of On-Demand Catastrophe Modelling Services, using...

APLS : 27.83 (+0.07%)
Joe Sechman Joins Bishop Fox as Associate Vice President of Applied Research and Development

Bishop Fox, the largest private professional services firm focused on offensive security testing, announced today that Joe Sechman has joined the firm as Associate Vice President of Applied Research and...

APLS : 27.83 (+0.07%)
Apellis Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria

Apellis Pharmaceuticals Inc. (NASDAQ: APLS) announced today the dosing of the first patient in the Phase 3 clinical study PRINCE (APL2-308), evaluating the efficacy and safety of APL-2 for treatment-naive...

APLS : 27.83 (+0.07%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 27.83 (+0.07%)
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 27.83 (+0.07%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 27.83 (+0.07%)
Apellis Pharmaceuticals Reports Second Quarter 2019 Business Update and Financial Results

Completed Enrollment in Phase 3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Head-to-Head Study in Patients Treated with Eculizumab; Top-line Data Anticipated in December 2019

APLS : 27.83 (+0.07%)
CVD Receives Applied Research & Development Award for Continued Development of ECMO Devices

CVD Equipment Corporation (NASDAQ: CVV), a leading provider of chemical vapor deposition systems and materials, announced today that it has received an Applied Research & Development (ARaD) award in collaboration...

APLS : 27.83 (+0.07%)
CVV : 3.25 (-2.69%)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement...

APLS : 27.83 (+0.07%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +4.48 , AIZ -0.27 , SBAC +4.06 , SO +0.08 , WELL +0.91
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar